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Abstract
Introduction: In Romania, no nationwide data for acromegaly treatment and control rate are available. Our objective was to assess the 
acromegaly control rate in a tertiary referral centre, which covers an important part of Romanian territory and population of patients 
with acromegaly.
Materials and methods: We reviewed the records of all 164 patients (49 males and 115 females; median age 55 [47, 63.5] years) with newly 
or previously diagnosed acromegaly, who have been assessed at least once in our tertiary referral centre between January 1, 2012 and 
March 31, 2016. This sample represents 13.6% of the total expected 1200 Romanian patients with acromegaly and covers 82.9% of the 
counties in Romania. Control of acromegaly was defined as a random serum growth hormone (GH) < 1 ng/mL and an age-normalised 
serum insulin-like growth factor-I (IGF-I) value. The GH and IGF-I values used for calculation of the control rate were those at the last 
evaluation. The same assays for GH and IGF-I measurement were used in all patients.
Results: There were 147 treated and 17 untreated patients. Of the 147 patients assessed after therapy, 137 (93.2%) had pituitary surgery, 
116 (78.9%) were on medical treatment at the last evaluation, and 67 (45.5%) had radiotherapy. Seventy-one (48.3%) had a random 
GH < 1 ng/mL, 54 (36.7%) had a normalised, age-adjusted IGF-I, and 42 (28.6%) had both normal random serum GH and IGF-I.
Conclusions: In Romania, acromegaly benefits from the whole spectrum of therapeutic interventions. However, the control rate remains 
disappointing. (Endokrynol Pol 2017; 68 (5): 519–523)
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Streszczenie
Wstęp: W Rumunii nie są dostępne ogólnokrajowe dane dotyczące leczenia akromegalii ani wskaźnika kontroli choroby. Badanie prze-
prowadzono w celu oceny wskaźnika kontroli akromegalii w ośrodku referencyjnym trzeciego stopnia, który obejmuje opieką zdrowotną 
znaczną część obszaru Rumunii i populacji pacjentów z akromegalią.
Materiał i metody: Autorzy dokonali przeglądu danych medycznych wszystkich 164 chorych [49 mężczyzn i 115 kobiet; mediana wieku 
55 lat (47; 63,5)] z noworozpoznaną lub wcześniej zdiagnozowaną akromegalią, których przynajmniej jednokrotnie zbadano w ośrodku 
referencyjnym trzeciego stopnia (miejsce pracy autorów) w okresie od 1 stycznia 2012 roku do 31 marca 2016 roku. Ta próba stanowiła 
13,6% całej rumuńskiej populacji chorych na akromegalię szacowaną na 1200 osób i reprezentowała 82,9% okręgów administracyjnych 
w Rumunii. Kontrolę akromegalii definiowano jako stężenie przygodne hormonu wzrostu (growth hormone, GH) w surowicy wynoszące 
poniżej 1 ng/ml oraz normalizacja odpowiednio do wieku stężenia insulinopodobnego czynnika wzrostu 1 (insulin-like growth factor-1, 
IGF-1) w surowicy. Do obliczenia wskaźnika kontroli choroby stosowano wartości GH i IGF-1 z ostatnich pomiarów. U wszystkich pa-
cjentów używano tych samych testów do pomiarów GH i IGF-1.
Wyniki: Badanie obejmowało 147 chorych poddanych leczeniu i 17 chorych nieleczonych. Spośród 147 chorych ocenianych po terapii, 
u 137 (93,2%) zastosowano leczenie chirurgiczne, 116 (78,9%) w momencie ostatniej wizyty kontrolnej stosowało leczenie farmakologiczne, 
a 67 (45,5%) poddano radioterapii. U 71 chorych (48,3%) przygodne stężenie GH w surowicy wynosiło poniżej 1 ng/ml, u 54 (36,7%) uzyskano 
normalizację stężenia IGF-1 skorygowanego względem wieku, a u 42 chorych (28,6%) uzyskano normalizację obu parametrów — GH i IGF-1.
Wnioski: W Rumunii u chorych na akromegalię stosuje się szerokie spektrum interwencji terapeutycznych, jednak wskaźnik kontroli 
choroby nadal pozostaje niezadawalający. (Endokrynol Pol 2017; 68 (5): 519–523)
Słowa kluczowe: akromegalia, Rumunia, leczenie, wskaźnik kontroli choroby
Introduction
Uncontrolled acromegaly is a well-known cause of 
increased morbidity and mortality [1]. Recent decades 
have brought an improvement in acromegaly control, 
but, depending on the criteria used, it does not exceed 
68–95% of patients after surgery [2] or 75–90% of 
patients on medical treatment with somatostatin ana-
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logues (SSA) [3] or pegvisomant [4]. Moreover, there is 
an important heterogeneity in acromegaly control rates 
between centres [5–7] or between industry-sponsored 
clinical trials and real-life studies [4, 8]. In addition, 
a significant number of patients need a multimodal 
treatment approach including surgery, various medical 
therapies, and radiotherapy. These patients are rarely 
involved in randomised clinical trials.
The best tool to measure nationwide success in the 
treatment of acromegaly is a country-specific database 
or register covering as many patients as possible over 
a long period of time. At present, multiple country da-
tabases are functional throughout Europe [5–7, 9, 10]. 
Unfortunately, Romania does not have such a register, 
and no nationwide data for acromegaly treatment and 
control rate are available.
Our objective was to assess the acromegaly control 
rate in a tertiary referral centre, which covers an im-
portant part of Romanian territory and population of 
patients with acromegaly.
Materials and Methods
Subjects
Starting on January 1, 2012 the “C. I. Parhon” Institute 
of Endocrinology constantly used the same assays for 
serum growth hormone (GH) and insulin-like growth 
factor-I (IGF-I) measurement, according to the Endo-
crine Society Guidelines for Acromegaly [11]. Hence, 
we reviewed the charts of all patients with confirmed 
acromegaly, who were assessed at least once in our ter-
tiary referral centre between January 1, 2012 and March 
31, 2016. During this period we assessed 164 patients 
with newly or previously diagnosed acromegaly from 
34 counties. There were 49 males and 115 females, with 
a median age of 55 (47, 63.5) years. As the prevalence 
of acromegaly is considered to be around 60 cases per 
million [12] for an estimated Romanian population of 20 
million, our centre assessed 13.6% of the total expected 
1200 Romanian patients with acromegaly. Our popula-
tion covered 34 of the 41 Romanian counties (Bucharest 
and Ilfov county taken together), i.e. 82.9% (Fig. 1A).
Of the total 164 patients, 57 (34.7%) had newly 
diagnosed acromegaly. There were 15 males and 42 
females with a median age of 55 (43.7, 60.5) years. At 
an estimated incidence of 3-4 cases per million [10, 12]
due in the majority of cases to a GH-secreting pituitary 
adenoma, and occurring with a population prevalence 
of 60 per million and an incidence of 3-4 per million 
per year. Males and females appear to be equally af-
fected with an average age of presentation of 44 years. 
Younger patients may have more aggressive tumours 
and higher GH concentrations. There is co-existent 
hyperprolactinaemia in about one third of cases, and 
a variable proportion of [figure: see text] tumours ap-
pear to have activating mutations of the gsp gene or 
other genetic abnormalities. Acute complications such 
as carpal tunnel syndrome, sweating and obstructive 
sleep apnoea are usually readily reversible with treat-
ment of the condition, but chronic complications such as 
hypertension, diabetes and heart disease are less readily 
corrected and post-treatment GH levels of < 2.5 ug/L 
(5 mU/L per year, Romania should have 60–80 new cases 
of acromegaly per year. The estimated incidence for the 
51 months of the study is 13.4 new cases of acromegaly 
per year, 16.7–22.3% of the estimated Romanian patient 
population. This population covered 20 counties, 48.7% 
of Romanian territory (Fig. 1B).
Assays
Control of acromegaly was defined according to Endo-
crine Society guidelines [11]: a random serum GH < 
1 ng/mL and an age-normalised serum IGF-I value. The 
GH and IGF-I values used for calculation of the control 
rate were those at the last evaluation.
Serum GH was measured using a chemilumines-
cence assay (Liaison, Sallugia, Italy). The assay is refer-
enced to WHO Second International Standard 98/574 
for somatropin (22-kDa recombinant DNA-derived 
materials). The functional sensitivity is 0.05 ng/mL, and 
the analytical sensitivity is 0,009 ng/mL.
Serum IGF-I was measured using a Liaison IGF-I 
chemiluminescence assay (DiaSorin, Sallugia, Italy). The 
assay is referenced to the 02/254 International Stand-
ard for Insulin-like Growth Factor-I NIBSC. The assay 
functional sensitivity is 15 ng/mL, and the analytical 
sensitivity is 3 ng/mL.
Statistics
Data are presented as number (percentage) or median 
(25th, 75th percentile). Wilcoxon test was used to test 
differences between paired groups. A p value less than 
0.05 was considered statistically significant.
Results
Between January 1, 2012 and March 31, 2016 we as-
sessed 164 patients with newly or previously diagnosed 
acromegaly. There were 147 treated and 17 untreated 
patients. Of the 147 patients assessed after therapy, 
137 (93.2%) had pituitary surgery, 116 (78.9%) were 
on medical treatment at the last evaluation (51 on 
octreotide LAR, 33 on lanreotide PR or autogel, 15 on 
pegvisomant, 30 on cabergoline, and 10 were involved 
in clinical trials with SSA), and 67 (45.5%) had radio-
therapy (11 low-voltage radiotherapy, 27 high-voltage 
radiotherapy, and 36 gamma-knife; seven patients had 
two different radiotherapies).
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Of the 147 patients assessed after at least one treat-
ment, 71 (48.3%) had a random GH < 1 ng/mL, 54 
(36.7%) had a normalised age-adjusted IGF-I, and 42 
(28.6%) had both normal random serum GH and IGF-I.
Between January 1, 2012 and March 31, 2016 we 
diagnosed 57 patients with acromegaly. Of these, 42 
were also assessed after at least one treatment. Of the 
42 treated patients 20 (47.6%) had a random GH < 1 
ng/mL, 11 (26.2%) had a normalized age-adjusted IGF-I 
and 8 (19.0%) had both normal random serum GH and 
IGF-I. Treatment efficacy for different treatments can be 
found in Figure 2.
Forty-one patients diagnosed after January 1, 2012 
were treated by surgery. Surgery normalised random 
GH in 10 patients (24.4%), IGF-I in six patients (14.6%), 
and both GH and IGF-I in four patients (9.7%). The me-
dian random serum GH was lowered by surgery from 
8.7 (4.2, 22.4) ng/mL to 2.5 (1.2, 5.1) ng/mL (p < 0.001). 
Serum IGF-I was lowered by surgery from 3.6 (3.0, 4.2) 
X ULN to 2.6 (1.6, 3.4) X ULN (p < 0,001) (Fig. 3).
Somatostatin analogues were used in 26 patients 
not cured by surgery. SSA analogues normalised GH in 
11 patients (42.3%), IGF-I in five patients (19.2%), and 
both GH and IGF-I in four patients (15.4%). In these 
26 patients SSA lowered serum random GH from 3.1 
(2.1, 5.9) ng/mL to 1.4 (0.8, 3.7) g/mL (p = 0,009). Serum 
IGF-I was lowered from 3.0 (2.5, 3.5) X ULN to 1.5 (1.0, 
2.1) X ULN (p < 0,001) (Fig. 3).
Discussion
Our study presents the control rate of acromegaly in 
a sample of 164 patients assessed in a single tertiary 
centre between January 1, 2012 and March 31, 2016. 
Also, we present here the control rate and the GH and 
IGF-I lowering effect of different treatments in pa-
tients diagnosed after January 1, 2012. At an estimated 
prevalence of 60 cases per million and an estimated 
incidence of 3–4 cases per million [10, 12] per year, this 
population represents 13.6% of the total population 
of acromegalic patients and 16.7–22.3% of patients 
with newly diagnosed acromegaly in Romania. To our 
knowledge, it is the largest study on acromegaly control 
rate in Romania.
Surgery was the mainstay of acromegaly treatment. 
In our study, 95.1% of treated patients had pituitary sur-
gery, a slightly higher figured compared with data from 
national registries: 89.3% in Germany [5], 83.8% in Spain 
[9], 70.3% in UK [7], and 68% in Belgium [6]. Medical 
treatment for acromegaly came into widespread use in 
Romania only in the last 5-10 years and is reimbursed 
only in surgically treated patients, and this could explain 
the high percentage of surgery. On the other hand, 
78.9% of patients were on medical treatment at the last 
evaluation (SSA, GH receptor antagonists, dopamine 
agonists, or clinical trials) as compared with 74.7% in 
Spain [9], 60.2% in UK [7], 58% in Belgium [6], and 
42.6% in Germany [5]. The high percentage of patients 
on medical treatment in Romania is probably due to the 
very low cure rate of surgery (see below). Radiotherapy 
was used in 45.5% of patients as compared with 22.2% in 
Germany [5], 34% in Belgium [6], and 44.7% in UK [7]. In 
all of these countries the percentage of radiotherapy fell 
dramatically in recent decades, primary radiotherapy 
being practically absent. In Romania, of the 67 patients 
with radiotherapy, only seven (10.4%) were diagnosed 
after 2012, the remaining 60 (89.6%) being diagnosed 
prior to 2012.
We found an overall disease control rate (GH < 
1 ng/mL and age-normalised IGF-I) of 28.6%. This would 
increase to 36.7% if only an age-normalised IGF-I were 
considered and to 48.3% if only random GH < 1 ng/mL 
were used to define disease control. The UK acromegaly 
Register [7] reported a rate of age-normalised IGF-I of 
59% for patients assessed after 2000. The rate of GH and 
IGF-I control was 49%, but in this register normal GH 
A B
Figure 1. Geographical distribution of the prevalent (1A) and incident (1B) population of acromegalic patients from our centre between 
January 1, 2012 and March 31, 2016. The numbers represent individual patients from a particular county
Rycina 1. Rozkład geograficzny chorobowości (1A) i zapadalności (1B) w populacji chorych z akromegalią leczonych w ośrodku autorów 
w okresie od 1 stycznia 2012 roku do 31 marca 2016 roku. Przedstawiono liczę pacjentów z poszczególnych okręgów
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was defined as < 2 ng/mL. The German Acromegaly 
Register [5] reported a rate of age-normalised IGF-I of 
71.9%, a figure two times higher than in our results; 
GH data are not reported. The rate of age-normalised 
IGF-I was 56% in AcroBel [6] and 76% in the Spanish 
Acromegaly Registry [9]. Overall, the rates of disease 
control in patients from European national registers are 
20–40% higher than in Romania, probably due to the 
poor result of surgery (see below) in our country. Also, 
the pre-treatment GH but not IGF-I levels are known 
to have an impact on the disease control rate of medical 
therapy [8, 13]. However, in the subgroup of patients 
from our study submitted to somatostatin analogues 
the pre-treatment GH and IGF-I levels were 3.1 ng/mL 
and 3.0 X ULN, lower than in this meta-analysis [13].
In the subgroup of patients diagnosed after 2012 
surgery normalised GH, IGF-I, or both GH and IGF-I 
in 21.9%, 14.5%, and 9.7% of patients, respectively. The 
rate of normalised age-adjusted IGF-I by surgery alone 
is over 30% in national registers [5–7, 9]. This low control 
rate is unexpected because most of the surgical interven-
tions on our patients were carried out in a university 
tertiary neurosurgical unit with more than 50 pituitary 
surgeries per year. The number of pituitary surgical 
interventions is a well-accepted and important factor 
in surgical success [14–16]. However, although active 
postsurgical disease was the most frequent scenario, 
median random GH and IGF-I serum levels were sig-
nificantly lowered by pituitary surgery.
Somatostatin analogues seemed to have a lower 
efficacy in our population compared with published 
national registers [5–7]. However, not all patients were 
on maximal doses of SSA. Also, the number of the 
patients in the subgroup diagnosed after year 2000 
is too small (n = 26) to draw firm conclusions. As for 
surgery, SSA were able to significantly lower random 
GH and IGF-I serum levels.
Although our sample population represents 13.6% of 
the total population of acromegalic patients in Romania 
and covers most of its territory, the main limitation of 
our study is the absence of a real registry for acromegaly. 
In the European countries where a nationwide registry 
is functional [5–7, 9] it includes most of the acromegalic 
population and many practicing offices, from university 
centres to smaller regional hospitals. However, there 
are countries where acromegaly treatment is restricted 
to university centres [10]. Unfortunately, in our study, 
the practicing bias of a single centre cannot be ruled 
out. Also, there are 15 patients who were diagnosed 
after 2012, who were not reassessed after any kind of 
treatment. It is possible that some of these patients were 
cured by surgery and never returned to our centre, thus 
artificially lowering the cure rate.
To our knowledge it is the largest study on acromegaly 
control rate in Romania. Also, our study showed consist-
ency in patient assessment because we used the same assays 
Figure 2. Percentages of patients with normalised random GH 
(white bars), IGF-I (grey bars), or GH and IGF-I (black bars) in 
all treated patients (n = 147) or patients diagnosed after 2012 
(all treatments, n = 42; surgery, n = 41; somatostatin analogues, 
n = 26)
Rycina 2. Odsetek pacjentów z normalizacją stężeń hormonu 
wzrostu (growth hormone, GH) (białe słupki), insulinopodobnego 
czynnika wzrostu 1 (insulin-like growth factor-1, IGF-1) (szare 
słupki) oraz GH i IGF-1 (czarne słupki) w pomiarach przygodnych 
u wszystkich leczonych pacjentów (n = 147) oraz u pacjentów, 
u których rozpoznano chorobę po 2012 roku (wszystkie metody 
leczenia, n = 42; leczenie chirurgiczne, n = 41; analogi 
somatostatyny, n = 26)
Figure 3. Effect of surgery (n = 41, grey bars) and somatostatin 
analogues (n = 26, shaded bars) compared with baseline (n = 
41, white bars) on random serum GH (left Oy axis) and IGF-I 
(right Oy axis)
Rycina 3. Zmiana stężenia w surowicy hormonu wzrostu (growth 
hormone, GH) (lewa strona osi Y) i insulinopodobnego czynnika 
wzrostu 1 (insulin-like growth factor-1, IGF-1 (prawa strona osi Y) 
w pomiarach przygodnych pod wpływem leczenia chirurgicznego 
(n = 41, szare słupki) oraz terapii analogami somatostatyny (n 
= 26, zakreskowane słupki) w stosunku do stanu wyjściowego 
(n = 41, białe słupki)
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for ultrasensitive GH and IGF-I measurement during the 
whole period of the study, as recommended by the last ac-
romegaly guidelines [11]. Moreover, we defined acromegaly 
control based on the latest guidelines by using random GH 
instead of mean 24-h GH or minimum GH during an oral 
glucose tolerance test (OGTT) and age-normalised IGF-I 
[11]. There is a study on a larger population of 336 acromeg-
alic patients in Romania [17] containing also data on cure 
rate. However, it focused on mortality, used different criteria 
for acromegaly control definition, and GH was measured 
using an immunoradiometric assay. Unfortunately, also 
national registries from European countries use slightly 
different criteria for defining disease control. For example, 
the German Acromegaly Register [5] does not use GH levels 
(random, mean, or minimum during OGTT), and the UK 
Acromegaly Register uses a random GH cut-off value of 2 
ng/mL for the definition of acromegaly control [7].
Conclusions
In conclusion, in Romania acromegaly benefits from 
the whole spectrum of therapeutic interventions: 
pituitary surgery in high-volume centres, long-acting 
somatostatin analogues, GH receptor antagonist, and 
modern radiotherapy. However, the control rate re-
mains disappointing.
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